CSTL — CASTLE BIOSCIENCES INC
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1447362 ·
Last close
$32.98
Market Cap
$1.02B
52W High
$44.28
52W Low
$17.72
ADV30
404,523
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 102,891,000 | 78,972,000 | -2,731,000 | -4,100,000 | 579,408,000 | 77,994,000 | 100,964,000 |
| Jun 2026 | 103,546,000 | 79,846,000 | -3,070,000 | -2,060,000 | 561,177,000 | 62,116,000 | 91,147,000 |
| Mar 2026 | 83,679,000 | 63,146,000 | -18,407,000 | -14,522,000 | 547,805,000 | 63,764,000 | 86,389,000 |
| Dec 2025 | 87,010,000 | 68,695,000 | -3,827,000 | -2,332,000 | 578,556,000 | 116,729,000 | 107,683,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$42,634,000
Investing CF
$-51,324,000
Financing CF
$-11,427,000
CapEx
$-43,123,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.66
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-240,866,000
Inventory
$10,580,000
Receivables
$48,341,000
ST Investments
$204,689,000
EBIT TTM
$-18,828,000
Pretax Income TTM
$-19,203,000
Interest Exp TTM
$375,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$377,126,016
EBITDA
$-12,080,000
Free Cash Flow
$5,089,625
Enterprise Value
$761,119,808
Total Cash
$277,664,992
Total Debt
$36,574,000
Shares Out
30,818,291
Trailing EPS
$-0.76
Book Value
$15.55
ROE
-4.9%
ROA
-3.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 344,229,000 | -42,810,000 | -24,158,000 | 578,556,000 | 107,683,000 | 470,873,000 | 64,347,000 |
| Dec 2024 | 332,069,000 | 8,670,000 | 18,245,000 | 531,235,000 | 75,400,000 | 455,835,000 | 64,866,000 |
| Dec 2023 | 219,788,000 | -67,977,000 | -57,466,000 | 453,340,000 | 62,071,000 | 391,269,000 | -5,626,000 |
| Dec 2022 | 137,039,000 | -91,142,000 | -67,138,000 | 447,329,000 | 48,179,000 | 399,150,000 | -41,655,000 |
TTM Snapshot
Revenues TTM
$357,278,000
NetIncome TTM
$-19,415,000
OpCashFlow TTM
—
Assets (Latest)
$561,177,000
Forward EPS
$-0.69
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $25.00 · spot: $33.38 · call volume: 6 · put volume: 4Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AHCO | AdaptHealth Corp. | $1.03B | $7.53 | — |
| FRNM | Freenome, Inc. | $1.09B | $9.82 | — |
| OMDA | Omada Health, Inc. | $872.90M | $14.08 | — |
| PNTG | Pennant Group, Inc. | $1.28B | $36.50 | — |
| INNV | InnovAge Holding Corp. | $1.29B | $9.42 | — |
News headlines (Yahoo Finance, 1h cache)
Castle Biosciences (CSTL) Stock Could Be Undervalued Following Raised 2026 Guidance
2026-11-14 05:17 · Yahoo
Castle Biosciences (CSTL) Lifts Guidance Following Revenue Growth But Is The Valuation Already Priced In
2026-11-13 01:15 · Yahoo
Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture
2026-11-12 12:00 · Yahoo
Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference
2026-11-11 21:30 · Yahoo
DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging
2026-11-11 12:00 · Yahoo
Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 37%: Here's is How to Trade
2026-11-10 13:55 · Yahoo
Castle Biosciences Stock Gets A Lift From Raised 2026 Outlook
2026-11-06 18:19 · Yahoo
Castle Biosciences, Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
Castle Biosciences Inc (CSTL) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24% as ...
2026-11-06 11:17 · Yahoo
What Castle Biosciences (CSTL) Said on Its Q3 Earnings Call
2026-11-06 03:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.